[1] Wang D, Hu J, Deng C, et al.Predictive nomogram for central lymph node metastasis in papillary thyroid microcarcinoma based on pathological and ultrasound features[J]. Front Endocrinol (Lausanne), 2023, 14: 1108125. [2] Suzuki N, Watanabe N, Noh JY, et al.The Relationship Between Primary Thyroid Lymphoma and Various Types of Thyroid Autoimmunity: A Retrospective Cohort Study of 498 Cases, Including 9 Cases with Graves' Disease[J]. Thyroid, 2022, 32(5): 552-559. [3] Thieblemont C, Mayer A, Dumontet C, et al.Primary thyroid lymphoma is a heterogeneous disease[J]. J Clin Endocrinol Metab, 2002, 87(1): 105-111. [4] Walsh S, Lowery AJ, Evoy D, et al.Thyroid lymphoma: recent advances in diagnosis and optimal management strategies[J]. Oncologist, 2013, 18(9): 994-1003. [5] Carbone A, Roulland S, Gloghini A, et al.Follicular lymphoma[J]. Nat Rev Dis Primers, 2019, 5(1): 83. [6] Mourcin F, Pangault C, Amin-Ali R, et al.Stromal cell contribution to human follicular lymphoma pathogenesis[J]. Front Immunol, 2012, 3: 280. [7] Guilloton F, Caron G, Menard C, et al.Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes[J]. Blood, 2012, 119(11): 2556-2567. [8] Gonzalez-Sanchez C, Salvador-Egea MP, Gluckmann-Maldonado E, et al.Diagnosis and treatment of primary thyroid lymphoma from a surgical perspective: a multi-institutional study[J]. Langenbecks Arch Surg, 2023, 408(1): 206. [9] Suzuki A, Hirokawa M, Higashiyama T, et al.Flow cytometric, gene rearrangement, and karyotypic analyses of 110 cases of primary thyroid lymphoma: a single-institutional experience in Japan[J]. Endocr J, 2019, 66(12): 1083-1091. [10] Dreyling M, Ghielmini M, Rule S, et al.Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2021, 32(3): 298-308. [11] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会淋巴细胞疾病学组, 中国滤泡淋巴瘤工作组,等. 中国滤泡性淋巴瘤诊断与治疗指南(2023年版)[J]. 中华血液学杂志, 2023,44(7): 529-534. [12] Hamamoto Y, Kukita Y, Kitamura M, et al.Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma[J]. Histopathology, 2021, 79(4): 521-532. [13] Zelenetz AD, Gordon LI, Abramson JS, et al.NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019[J]. J Natl Compr Canc Netw, 2019, 17(6): 650-661. [14] Choi SM, Betz BL, Perry AM.Follicular Lymphoma Diagnostic Caveats and Updates[J]. Arch Pathol Lab Med, 2018, 142(11): 1330-1340. [15] Solal-Celigny P, Bellei M, Marcheselli L, et al.Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database[J]. J Clin Oncol, 2012, 30(31): 3848-3853. [16] Hiddemann W, Barbui AM, Canales MA, et al.Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety[J]. J Clin Oncol, 2018, 36(23): 2395-2404. [17] Schmitt CJ, Dietrich S, Ho AD, Witzens-Harig M.Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors[J]. Ann Hematol, 2012, 91(3): 391-397. [18] Sehn LH, Chua N, Mayer J, et al.Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2016, 17(8): 1081-1093. [19] Yang ZZ, Kim HJ, Wu H, et al.T-cell phenotype including CD57(+) T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma[J]. Blood Cancer J, 2023, 13(1): 124. [20] Burman KD, Ringel MD, Wartofsky L.Unusual types of thyroid neoplasms[J]. Endocrinol Metab Clin North Am, 1996, 25(1): 49-68. |